Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies

Non-clear cell renal cell carcinoma (nccRCC) tumours include a heterogeneous group of malignancies that profoundly differ in terms of morphology, genetic profile, clinical behaviour and prognosis. The optimal treatment algorithm for nccRCC is still unknown and derived mainly from evidence available...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2017-09, Vol.83, p.237-246
Hauptverfasser:	Ciccarese, Chiara, Iacovelli, Roberto, Brunelli, Matteo, Massari, Francesco, Bimbatti, Davide, Fantinel, Emanuela, De Marco, Vincenzo, Porcaro, Antonio Benito, Martignoni, Guido, Artibani, Walter, Tortora, Giampaolo
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Renal Cell - drug therapy Clinical trials Clinical Trials as Topic Comparative analysis Confidence intervals Disease-Free Survival Everolimus Histology Humans Inhibitors Kidney cancer Kidney Neoplasms - drug therapy Medical research Medical treatment Meta-analysis Molecular chains mTORi Non clear cell RCC Papillary RCC Patients Probability Prospective Studies Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase receptors Protein-Tyrosine Kinases - antagonists & inhibitors Randomization Rapamycin Renal cell carcinoma Risk Statistical analysis Sunitinib Survival Therapy TKi TOR protein TOR Serine-Threonine Kinases - antagonists & inhibitors Tumors Tyrosine Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular endothelial growth factor receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!